Natera (NASDAQ:NTRA) Earns Equal Weight Rating from Analysts at Wells Fargo & Company

Analysts at Wells Fargo & Company began coverage on shares of Natera (NASDAQ:NTRA) in a research report issued to clients and investors on Monday, Marketbeat reports. The firm set an “equal weight” rating and a $175.00 price target on the medical research company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 1.26% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Barclays reiterated an “overweight” rating and issued a $210.00 price objective (up from $190.00) on shares of Natera in a report on Friday, August 8th. Piper Sandler reissued an “overweight” rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Stephens reissued an “overweight” rating and set a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Morgan Stanley reissued an “overweight” rating and set a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Finally, Cowen reissued a “buy” rating on shares of Natera in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $192.88.

Natera Stock Down 3.5%

Natera stock opened at $172.83 on Monday. The company’s fifty day simple moving average is $157.68 and its 200-day simple moving average is $155.58. Natera has a 12 month low of $117.27 and a 12 month high of $183.00. The stock has a market cap of $23.72 billion, a P/E ratio of -90.49 and a beta of 1.68.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Natera will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $166.62, for a total value of $499,860.00. Following the transaction, the insider directly owned 120,859 shares of the company’s stock, valued at approximately $20,137,526.58. This trade represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 2,496 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $133.17, for a total transaction of $332,392.32. Following the completion of the transaction, the director directly owned 5,763 shares in the company, valued at approximately $767,458.71. The trade was a 30.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,423 shares of company stock valued at $8,459,656 over the last three months. Insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after acquiring an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Natera by 44.3% in the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares during the last quarter. Geode Capital Management LLC raised its holdings in Natera by 7.0% in the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after purchasing an additional 166,768 shares during the period. Finally, Invesco Ltd. raised its holdings in Natera by 13.7% in the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after purchasing an additional 245,719 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.